title: Stimulated human melanocytes express and release interleukin-8, which is inhibited by luteolin: relevance to early vitiligo.
abstract: Vitiligo is a disorder of depigmentation, for which the pathogenesis is as yet unclear. Interleukin (IL)-8 (CXCL8) is a key inflammatory chemokine. We investigated the regulation of IL-8 production in human melanocytes, and the IL-8 serum levels and skin gene expression in patients with vitiligo and in controls. Cultured melanocytes were stimulated for 24 h with tumour necrosis factor (TNF) 100 ng/mL and IL-1β 10 ng/mL, with or without pretreatment with luteolin 50 μmol/L for 30 min, and IL-8 release was measured by ELISA. Serum cytokines were measured by a microbead array. Skin biopsies were taken from healthy subjects (n = 14) as well as from marginal lesional and nonlesional skin from patients with vitiligo (n = 15). IL-8 gene expression was evaluated by quantitative real time PCR. Both TNF and IL-1β stimulated significant IL-8 release (P < 0.01) from melanocytes, whereas pretreatment with luteolin significantly inhibited this effect (P < 0.01). IL-8 gene expression was significantly increased in vitiligo compared with control skin (P < 0.05). IL-8 may be involved in vitiligo inflammation. Inhibition by luteolin of IL-8 release could be useful for vitiligo therapy.
authors.affiliation: Molecular Immunopharmacology and Drug Discovery Laboratory, Department of Molecular Physiology and Pharmacology, Tufts University School of Medicine, Boston, MA, USA; First Department of Dermatology, A. Sygros Hospital, Athens University Medical School, Athens, Greece.
authors.forename: A
authors.initials: A
authors.lastname: Miniati
authors.forename: Z
authors.initials: Z
authors.lastname: Weng
authors.forename: B
authors.initials: B
authors.lastname: Zhang
authors.forename: A
authors.initials: A
authors.lastname: Therianou
authors.forename: M
authors.initials: M
authors.lastname: Vasiadi
authors.forename: E
authors.initials: E
authors.lastname: Nicolaidou
authors.forename: A J
authors.initials: AJ
authors.lastname: Stratigos
authors.forename: C
authors.initials: C
authors.lastname: Antoniou
authors.forename: T C
authors.initials: TC
authors.lastname: Theoharides
mesh_terms: D000328:Adult; D016022:Case-Control Studies; D002478:Cells, Cultured; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D020869:Gene Expression Profiling; D006801:Humans; D053583:Interleukin-1beta / Q000494:pharmacology; D015850:Interleukin-6 / Q000378:metabolism; D016209:Interleukin-8 / Q000378:metabolism*; D047311:Luteolin / Q000494:pharmacology*; D008297:Male; D008544:Melanocytes / Q000187:drug effects* / Q000378:metabolism; D008875:Middle Aged; D012867:Skin / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism; D014820:Vitiligo / Q000188:drug therapy / Q000378:metabolism*
chemical_list: D053583:Interleukin-1beta; D015850:Interleukin-6; D016209:Interleukin-8; D014409:Tumor Necrosis Factor-alpha; D042461:Vascular Endothelial Growth Factor A; D047311:Luteolin